PRRT2 and neoplasm: Indeed, mice injected with YTS-2DL1 SHP-1-deficient/catalytically inactive cells that were treated with PKC-θ siRNA demonstrated slower tumor growth rates and smaller tumor volumes compared to mice injected with WT NK cells (Figure 8).